Register for email alerts and news feeds:
This journal | BMJ Group
rss
Journal of Clinical Pathology 2003;56:271-276; doi:10.1136/jcp.56.4.271
Copyright © 2003 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.
Journal of Clinical Pathology 2003;56:271-276
© 2003 BMJ Publishing Group & Association of Clinical Pathologists

ORIGINAL ARTICLE

There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesions

H Chauhan1, A Abraham1, J R A Phillips2, J H Pringle3, R A Walker2 and J L Jones2

1 Department of Pathology, University Hospitals of Leicester NHS Trust, Leicester LE2 7LX, UK
2 Breast Cancer Research Unit, Department of Pathology, University of Leicester, Glenfield Hospital, Groby Road, Leicester LE3 9QP, UK
3 Department of Pathology, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, UK

Correspondence to:
Correspondence to:
Dr J L Jones, Breast Cancer Research Unit, Department of Pathology, University of Leicester, Glenfield Hospital, Groby Road, Leicester LE2 2BB, UK;
lj17{at}le.ac.uk

Aims: Smooth muscle actin (SMA) positive myofibroblasts have been implicated in tumour invasion; however, acquisition of SMA is not limited to peritumorous fibroblasts and other changes in fibroblasts may be more specifically related to the malignant environment. CD34 is a sialomucin expressed by normal breast fibroblasts but lost in invasive carcinomas. The aim of this study was to establish the relation between CD34 and SMA expression in breast fibroblasts and to analyse whether loss of CD34 is specific for invasive disease.

Methods: Immunohistochemistry for CD34 and SMA was performed on 135 cases including 10 normal, 10 fibroadenomas, 40 infiltrating ductal carcinomas, 55 cases of ductal carcinoma in situ (DCIS), and 20 radial scar/complex sclerosing lesions. The relation between staining pattern and histopathological features was recorded as positive, negative, or reduced.

Results: Fibroblasts around all normal duct–lobule units and those showing epithelial hyperplasia were CD34 positive and mainly SMA negative. In fibroadenomas, fibroblasts retained CD34 but acquired SMA expression. In contrast, fibroblasts around invasive carcinoma were CD34 positive and SMA negative. In DCIS, loss of CD34 was significantly more frequent in high grade tumours than in low or intermediate grade ones (p < 0.001). The acquisition of SMA was seen more frequently than the loss of CD34, particularly in non-high grade DCIS. In all radial scars, fibroblasts were SMA positive but CD34 negative, and a similar pattern was seen in stromal cells in areas of fibrosis following core biopsy.

Conclusions: These results show that SMA positive myofibroblasts exhibit variable expression of CD34, indicating that these markers are not coordinately controlled. Loss of CD34 is strongly related to the malignant phenotype, in both invasive and preinvasive disease, but is not entirely specific because radial scar fibroblasts and fibroblasts in reactive fibrosis exhibit a similar phenotype. The functional relevance of altered CD34 expression is unclear but the very focal changes implicate local signalling mechanisms probably of epithelial origin.

Keywords: CD34; breast; myofibroblast

Abbreviations: ADH, atypical ductal hyperplasia; DCIS, ductal carcinoma in situ; HPSC, haemopoietic stem/progenitor cell; HUT, usual type epithelial hyperplasia; IDC, infiltrating ductal carcinoma; LCIS, lobular carcinoma in situ; MMP, matrix metalloproteinase; SMA, smooth muscle actin


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Muehlberg, F. L., Song, Y.-H., Krohn, A., Pinilla, S. P., Droll, L. H., Leng, X., Seidensticker, M., Ricke, J., Altman, A. M., Devarajan, E., Liu, W., Arlinghaus, R. B., Alt, E. U. (2009). Tissue-resident stem cells promote breast cancer growth and metastasis. Carcinogenesis 30: 589-597 [Abstract] [Full Text]  
  • Mishra, P. J., Mishra, P. J., Humeniuk, R., Medina, D. J., Alexe, G., Mesirov, J. P., Ganesan, S., Glod, J. W., Banerjee, D. (2008). Carcinoma-Associated Fibroblast-Like Differentiation of Human Mesenchymal Stem Cells. Cancer Res. 68: 4331-4339 [Abstract] [Full Text]  
  • Gioni, V., Karampinas, T., Voutsinas, G., Roussidis, A. E., Papadopoulos, S., Karamanos, N. K., Kletsas, D. (2008). Imatinib Mesylate Inhibits Proliferation and Exerts an Antifibrotic Effect in Human Breast Stroma Fibroblasts. Mol Cancer Res 6: 706-714 [Abstract] [Full Text]  
  • Gomperts, B. N., Strieter, R. M. (2007). Fibrocytes in lung disease. J. Leukoc. Biol. 82: 449-456 [Abstract] [Full Text]  
  • Lithgow, D., Covington, C. (2005). Chronic Inflammation and Breast Pathology: A Theoretical Model. Biol Res Nurs 7: 118-129 [Abstract]  
  • Kuroda, N., Sugimoto, T., Takahashi, T., Moriki, T., Toi, M., Miyazaki, E., Hiroi, M., Enzan, H. (2005). Invasive Micropapillary Carcinoma of the Breast: An Immunohistochemical Study of Neoplastic and Stromal Cells. INT J SURG PATHOL 13: 51-55 [Abstract]  
  • Direkze, N. C., Hodivala-Dilke, K., Jeffery, R., Hunt, T., Poulsom, R., Oukrif, D., Alison, M. R., Wright, N. A. (2004). Bone Marrow Contribution to Tumor-Associated Myofibroblasts and Fibroblasts. Cancer Res. 64: 8492-8495 [Abstract] [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Pathology jobs

Pathology jobs